Posts

A fascination with chromosome rescue in uniparental disomy: Mendelian recessive outlaws and imprinting copyrights infringements

Image
x chromosome dominant disease :: Article Creator Mendelian Genetics: Patterns Of Inheritance And Single-Gene Disorders Autosomal recessive single-gene diseases occur only in individuals with two mutant alleles of the disease-associated gene. Remember, for any given gene, a person inherits one allele from his or her mother and one allele from his or her father. Therefore, individuals with an autosomal recessive single-gene disease inherit one mutant allele of the disease-associated gene from each of their parents. In pedigrees of families with multiple affected generations, autosomal recessive single-gene diseases often show a clear pattern in which the disease "skips" one or more generations. Phenylketonuria (PKU) is a prominent example of a single-gene disease with an autosomal recessive inheritance pattern. PKU is associated with mutations in the gene that encodes the enzyme phenylalanine hydroxylase (PAH); when a person has these muta...

Fig. 5A. GTG-banded partial metaphase of boy with Ochoa syndrome...

Image
thalassemia and sickle cell anaemia :: Article Creator Iron Overload Associated With Elevated Fracture Risk Iron overload is associated with increased risk for fracture, published in the Journal of Clinical Endocrinology and Metabolism. Hereditary hemochromatosis, thalassemia major, and sickle cell anemia are associated with higher iron accumulation and poor bone mineral density. However, the effects of iron overload on fracture risk are not well understood. Investigators from ETH Zurich in Switzerland and Technische Universität Dresden in Germany conducted a population-based cohort study using data from the IQVIA medical research database which is a longitudinal cohort comprising more than 800 general practices in the United Kingdom. Patients (n=20,264) with iron overload or an incident diagnosis of thalassemia major, sickle cell disease, or hemochromatosis were matched with up to 10 control participants (n=192,956). The primary outcome was f...

The Italian breakthrough in CRISPR trials for rare diseases: a focus on beta-thalassemia and sickle cell disease treatment

Image
ultra rare blood disorders :: Article Creator Top 5 Most-Read Articles On Rare Blood Disorders In 2024 Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia, and hemophilia, stressing the importance of early detection and innovative therapies. As research into rare blood disorders advances, 2024 has seen research illuminate the challenges and breakthroughs in diagnosis and treatment. Key findings focused on conditions like vaccine-induced immune thrombotic thrombocytopenia (VITT), immune thrombocytopenia (ITP), and hemophilia, stressing the importance of early detection and innovative therapies. Additionally, disparities in health outcomes for populations such as those with sickle cell disease (SCD) have come to the forefront. The top 5 most-read articles related to rare blood disorders in 2024. Image Credit: angellodeco - stock.Adobe.Com Read more about 2024...

Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management

Image
45 chromosomes disorder :: Article Creator An Overview Of X-Linked Disorders And X Chromosome Aneuploidies Numerical disorders of the X chromosomeX-Linked disordersDiagnosis of X chromosome disordersManagement and support for X chromosome disorders    ReferencesFurther reading Numerical disorders of the X chromosome Chromosomal abnormalities can include two basic categories: numerical or structural. A structural abnormality can include an alteration to the structure of the chromosome, as the name suggests. However, a numerical abnormality means that an individual is either missing one of the chromosomes from its pair or that the individual has more than two chromosomes.1 The number of chromosomes in the human cell includes 46, with 23 pairs, one set being inherited from the egg provided by the biological mother and the other set of 23 chromosomes being inherited from the sperm provided by the biological father.1 The first 22 pairs are kno...

Advancements and Applications of Preimplantation Genetic Testing in In Vitro Fertilization: A Comprehensive Review

Image
treatment of coagulation disorders :: Article Creator Saliva Activates Coagulation In Persons With Hemophilia A A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that saliva contains special vesicles that trigger rapid coagulation of the blood of haemophilic patients. The results, which were recently published in the scientific journal Blood, contribute significantly to a better understanding of the disease. Haemophilia is a hereditary blood disorder characterised by a deficiency of certain coagulation factors, which can lead to life-threatening bleeding if left untreated. Why haemophilia A (with factor VIII deficiency) often leads to joint bleeding, but rarely to mucosal bleeding, was previously unclear. In search of an explanation, the scientific team led by Johannes Thaler and Cihan Ay (Clinical Divisio...

A fascination with chromosome rescue in uniparental disomy: Mendelian recessive outlaws and imprinting copyrights infringements

Image
muscular dystrophy hereditary :: Article Creator Insmed's Gene Therapy Poised To Challenge DMD Landscape After IND Clearance Duchenne muscular dystrophy (DMD) is a rare genetic disorder that is characterised by progressive muscle degeneration and weakness, and is caused by mutations in the dystrophin gene. Currently, the DMD treatment landscape includes Sarepta's Elevidys (delandistrogene moxeparvovec), the first FDA-approved gene therapy for DMD, which delivers a micro-dystrophin gene via an intravenous route. However, Insmed is set to challenge this space with its innovative gene therapy asset, INS1201. Following FDA clearance of its investigational new drug (IND) application in December 2024, Insmed plans to initiate Phase I clinical trials for INS1201 in H1 2025, according to an announcement during the JP Morgan 43rd Annual Healthcare Conference, held from 13 to 16 January in San Francisco, California, US. Unlike Elevidys, which requ...